Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-Targeted Dendritic Cell Vaccination in H3 G34-Mutant Diffuse Hemispheric Glioma
NCT06342908Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neoantigen-targeted ppDC vaccine in diffuse hemispheric glioma (DHG), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of regimen-limiting toxicities at 120 days. Started Jun 2024; status: active, not recruiting.
02
Drugs
neoantigen-targeted ppDC vaccine
03
Conditions
diffuse hemispheric glioma (DHG)
Beyond the preview
Go deeper on NCT06342908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342908.